Stablepharma Ltd Investors
Problem: Over 50% of vaccines are wasted, mainly due to poor refrigeration. Solution: Stablepharma's novel technology, StablevaXв„ў has shown strong in-vitro and in-vivo data on stabilising a range of vaccines including Tetadif (Td) and naked COVID mRNA. This patented invention stabilises existing approved vaccines, so that they can then be transported and stored for years without refrigeration, whilst complying with the protocols set by the WHO.
%20.jpg)
Technology:
Other
Industry:
Other
Founded Date:
2012
Investor Type:
Pharma Company
Employee Number:
1-10
Headquarters:
Bath, Bath and North East Somerset, United Kingdom